<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58769">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01991834</url>
  </required_header>
  <id_info>
    <org_study_id>MPFabiola</org_study_id>
    <nct_id>NCT01991834</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis in Gynecologic Laparoscopy</brief_title>
  <official_title>Antibiotic Prophylaxis in Gynecologic Laparoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade do Vale do Sapucai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade do Vale do Sapucai</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopy is a surgical procedure indicated for most gynecological pathologies and
      presents numerous advantages over laparotomy, among them lower rates of surgical site
      infection and less comorbidity feverish. Despite this, the use of antibiotic prophylaxis is
      widely accepted and performed by most gynecologists. However, there isn't literature
      evidence to support the routine use of antibiotics in the prophylaxis of wound infection on
      laparoscopic pelvic surgery .Therefore, this study will evaluate the need for the use of
      antibiotic prophylaxis in gynecological laparoscopies not including opening hollow viscera.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a clinical, prospective, double-blind, randomized study. 114 women with gynecologic
      disease, in which there is indication of laparoscopic surgical approach, will be
      consecutively select. These women will be allocated in two arms, control and study, where
      control group will use placebo and study will receive intravenous cephazolin. These patients
      will be followed for 30 days according to Centers for Disease Control and Prevention
      criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Surgical site infection</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients are followed weekly by a masked surgeon in regard to surgical site infecton (SSI), until the 30th postoperative day. Centers for Disease Control and Prevention's (CDC) criteria and classification were adopted.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Infection Secondary to Surgical Procedure</condition>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gynecologic laparoscopy</intervention_name>
    <description>Gynecological laparoscopy without opening hollow viscera.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Cefazolin</arm_group_label>
    <other_name>pelvic laparoscopy</other_name>
    <other_name>gynecologic laparoscopic surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Intravenous administration of 1 g of cefazolin</description>
    <arm_group_label>Cefazolin</arm_group_label>
    <other_name>Cephazolin</other_name>
    <other_name>Cefazoline</other_name>
    <other_name>Cephazolin Sodium for Injection</other_name>
    <other_name>Kefzol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous administration of saline sterile solution</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with gynecologic disease, undergoing gynecologic laparoscopy without opening
             hollow viscera.

        Exclusion Criteria:

          -  body mass index over 30 Kg/m2

          -  smoking

          -  diabetes type I or II with glycated hemoglobin exceeding 6.5%

          -  patients who are at surgical risk classification of the American Society of
             Anesthesiologists(ASA) as ASA III or higher

          -  refusal to participate

          -  postoperative antibiotic therapy for another indication clinical complication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabiola SM Campos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade do Vale do Sapucai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniela F Veiga, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidade do Vale do Sapucai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabiola SM Campos, MD</last_name>
    <phone>553534235988</phone>
    <email>fabiolasmc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clinicas Samuel Libanio</name>
      <address>
        <city>Pouso Alegre</city>
        <state>Minas Gerais</state>
        <zip>37550-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvania CV Archangelo, MD, PhD</last_name>
      <phone>553534235988</phone>
      <email>silvaniavieira@mastercabo.com.br</email>
    </contact>
    <investigator>
      <last_name>Silvania CV Archangelo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Marcos C Francisco, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital e Maternidade Santa Paula</name>
      <address>
        <city>Pouso Alegre</city>
        <state>Minas Gerais</state>
        <zip>37550-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabiola S Campos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabiola S Campos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 29, 2013</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade do Vale do Sapucai</investigator_affiliation>
    <investigator_full_name>Fabiola Soares Moreira Campos</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>gynecologic surgical procedures</keyword>
  <keyword>laparoscopy</keyword>
  <keyword>surgical wound infection</keyword>
  <keyword>antibiotic prophylaxis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
